TCRX Tscan Therapeutics Inc
Company Analysis
Latest News
🟢 Tscan Therapeutics Inc is trading 5.37% up in after-hours
TCRX is trading at $1.03, up 5.37% in after-hours.
🟢 TCRX is trading 6.8% up today after announcing positive initial data from its ALLOHA™ Phase 1 study
• TCRX is trading at $1.03 (6.8% up) following the announcement of positive initial data from Cohort C of its ALLOHA™ Phase 1 study evaluating TSC-101. • The...
🔴 TCRX is trading 8.6% down today following an earlier intraday surge
TCRX is trading at $0.89 (8.6% down) in after-hours trading as the stock pulls back from a sharp 11.1% intraday rally earlier on June 26, 2026. • No fresh...
🟢 TCRX makes sharp 11.1% jump
TCRX is trading at $0.93, up 11.1% versus the comparison close of $0.84 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 TCRX is trading 5.9% up today following positive Phase 1 ALLOHA study data
TCRX is trading at $0.89 (up 5.9%) in after-hours trading as investors digest positive initial data from the ALLOHA Phase 1 study of TSC-101. • The stock is...
🔴 TCRX is trading 5.24% down today, potentially weighing recent positive Phase 1 data
TCRX is trading at $0.83 (-5.24%) following a weak open. • The downward move follows recent positive initial data from its ALLOHA™ Phase 1 study for TSC-101 in...
TScan's Blood Cancer Therapy Shows Early Promise, but Can a Sub-Dollar Stock Survive Long Enough to Prove It?
Shares of TScan Therapeutics jumped +9% to $0.94 after the company unveiled encouraging early results from its lead cancer therapy — an engineered immune-cell...
🟢 TCRX is trading 9% up today on positive Phase 1 data for TSC-101
TCRX is trading at $0.94 (+8.99%) after TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA Phase 1 study for TSC-101 in hematologic...
TScan Announces Positive Phase 1 Data for TSC-101 in Heme Malignancies
TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA™ Phase 1 study for TSC-101 in patients with hematologic (heme) malignancies. The...
🟢 Tscan Therapeutics Inc is trading 5.2% up today after presenting positive data from its ALLOHA™ Phase 1 study
• Tscan Therapeutics Inc. presented positive data today from Cohort C of its ALLOHA™ Phase 1 study, evaluating TSC-101 in patients with heme malignancies. • 11...
🟢 Tscan Therapeutics Inc is trading 5.9% up today as it recovers from yesterday's sharp drop
Tscan Therapeutics Inc is trading at $0.90, up 5.9%, as the stock bounces back from a significant 10.8% decline in the previous session. • The move appears to...
🔴 Tscan Therapeutics Inc makes sharp 10.8% drop
TCRX is trading at $0.85, down 10.8% versus the comparison close of $0.95 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 Tscan Therapeutics Inc is trading 5.6% down today on normal volatility and giveback of recent gains
Tscan Therapeutics Inc is trading 5.6% down today at $0.90 as the stock experiences normal volatility and a giveback of recent gains. • The decline follows a...
🟢 Tscan Therapeutics Inc is trading 4.5% up today on broad risk-on rally following U.S.–Iran peace deal
Tscan Therapeutics Inc is trading 4.5% up at $0.95 as part of a broad risk-on rally triggered by a tentative U.S.–Iran peace agreement. • The stock bounced...
🟢 Tscan Therapeutics Inc is trading 5.3% up today amid broad risk-on sentiment following a U.S.–Iran peace agreement
Tscan Therapeutics Inc is trading 5.3% up at $0.96 in pre-market action, tracking a broad risk-on tone in U.S. equity futures as markets react to geopolitical...